Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

L. Sellner*, J. Schetelig, L. Koster, G. Choi, D. Blaise, D. Beelen, F.C. Schianca, J. Passweg, U. Schanz, E. Gyan, F. Sora, N. Kroger, G.G. Wulf, G. Van Gorkom, J. Mayer, C. Orvain, J.H. Bourhis, P. Jindra, V. Potter, F. ZallioE. Vandenberghe, S. Robinson, P.J. Hayden, I. Yakoub-Agha, S. Montoto, P. Dreger, European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Pages (from-to)2335-2338
Number of pages4
JournalBone Marrow Transplantation
Volume55
Issue number12
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • inhibition
  • outcomes
  • rituximab
  • trial
  • TRIAL
  • INHIBITION
  • RITUXIMAB
  • OUTCOMES

Cite this